FreshRSS

🔒
△ 🔃
☐ ☆ ✇ Evidence-Based Nursing

Remission of type 2 diabetes is achievable in primary care with intensive lifestyle intervention

Por: Zoungas · S. · Sumithran · P. — Junio 19th 2025 at 10:25

Commentary on: Hocking SL et al. Intensive Lifestyle Intervention for Remission of Early Type 2 Diabetes in Primary Care in Australia: DiRECT-Aus. Diabetes Care 2024;47:66–70.

Implications for practice and research

  • Intensive lifestyle intervention in primary care can safely achieve type 2 diabetes (T2D) remission at 12 months in around half of selected participants with short-duration, well-controlled T2D.

  • Research on the effectiveness and acceptability of strategies to improve durability of remission is needed.

    • Context

    Although previously thought to be inevitably progressive, evidence is growing that type 2 diabetes (T2D) can be brought into remission with weight loss.

    This study by Hocking et al1 was a single-arm replication of the Diabetes Remission Clinical Trial (DiRECT) randomised controlled trial2 in an Australian setting. It confirms that with an intensive lifestyle intervention including total diet replacement (TDR), around half of adults with recently...
    ☐ ☆ ✇ BMJ Open

    STatin TReatment for COVID-19 to Optimise NeuroloGical recovERy (STRONGER): study protocol for a randomised, open label clinical trial in patients with persistent neurological symptoms after COVID-19 infection

    Por: Delfino · C. · Carcel · C. · Lin · X. · Munoz-Venturelli · P. · Naismith · S. L. · Woodward · M. · Peters · R. · Wijesuriya · N. · Law · M. · Harding · I. H. · Wang · X. · Elliott · J. · Leder · K. · Hutchings · O. · Stecher · X. · Zoungas · S. · Anderson · C. S. — Abril 14th 2025 at 16:23
    Introduction

    Increasing awareness of the high frequency, wide spectrum and disabling nature of symptoms that can persist following COVID-19 infection has prompted the investigation of management strategies. Our study aims to determine the effectiveness of atorvastatin on cognitive function, physical activity, mood, health-related quality of life and features of neurovascular impairment and neuroinflammation in adults with ongoing neurological symptoms after COVID-19 infection.

     Methods and analysis

    The STatin TReatment for COVID-19 to Optimise NeuroloGical recovERy study is an ongoing international, investigator-initiated and conducted, multicentre, prospective, randomised, open label, blinded endpoint trial with fixed time points for outcome assessments. A total of 410 participants with long covid neurological symptoms were planned to be randomly assigned to either the intervention group to receive 40 mg atorvastatin for 12 months or to a control group of no treatment, on top of usual care.

     Ethics and dissemination

    This study protocol was designed, implemented and reported, in accordance with the International Conference on Harmonisation guidelines for Good Clinical Practice, the National Health and Medical Research Council of Australia, the National Statement on Ethical Conduct in Human Research and with the ethical principles laid down in the World Medical Association Declaration of Helsinki. Central ethics committee approval was obtained from Sydney Local Health District Royal Prince Alfred Hospital Ethics (No: X21-0113 and 2021/ETH00777 10) in Australia. Site-specific ethics committee approvals were obtained elsewhere before any local study activities. All participants provided written informed consent.

     Trial registration number

    The study protocol is registered at Clinicaltrials.gov (NCT04904536).
    ❌